Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trialKelly L. Bolton, Eytan M. Stein, Namrata S. Chandhok et al.|Blood|2025Cited by 2